Organization (Industry)
PENTAX Medical Company (United States)
ClinicalTrials.gov lists PENTAX Medical Company (United States) as lead sponsor of 10 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PENTAX Medical Company (United States): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Barrett Esophagus | 10 |
| Esophageal Neoplasms | 5 |
| Head and Neck Neoplasms | 5 |
| Colonic Polyps | 2 |
| Colorectal Neoplasms | 2 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 4 |
| 2015 | 2 |
| 2014 | 2 |
| 2011 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | 1 of 3 on time (n=3) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gastrointestinal endoscopy | 11 |
| Gastroenterology | 2 |
| The American journal of gastroenterology | 2 |
| Annals of internal medicine | 1 |
FDA recalls (26)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Bronchoscope Intended to provide optical visualization of and therapeutic access to the Airway and Bronchial Tree. This anatomy includes, but is not restricted to, the organs, tissues and subsystems: Nasal Passage, Trachea and Bronchial Tree. The instrument is introduced via the mouth or the nose, as decided by the physician, when indications consistent with the need for procedure are observed in adult and pediatric patient populations. | Class II | 2016-04-06 |
| Choledocho-Nephroscope Intended to provide optical visualization of and therapeutic access to the Abdominal Cavity. This anatomy includes, but is not restricted to, the organs, tissues and subsystems: Biliary tree with access to the Common bile Duct, Hepatic Duct, Cystic Duct, Kidney, Renal Cavity and Renal Calyces. The instrument is introduced via percutaneous cut when indications consistent with the need for procedure are observed in adult and pediatric patient populations. | Class II | 2016-04-06 |
| Choledochoscope Intended to provide optical visualization of and therapeutic access to the Biliary Tree. This anatomy includes, but is not restricted to, the organs, tissues and subsystems: Common Bile, Hepatic, Cystic and Pancreatic Ducts. The instrument is introduced via the working channel of a Duodenoscope positioned for access to the Common bile Duct when indications consistent with the need for procedure are observed in adult and pediatric patient populations. | Class II | 2016-04-06 |
| Colonoscope Intended to provide optical visualization of and therapeutic access to the Lower Gastrointestinal Tract. This anatomy includes, but is not restricted to, the organs, tissues and subsystems: Large Bowel to the Cecum. The instrument is introduced via the rectum when indications consistent with the need for procedure are observed in adult and pediatric patient populations. | Class II | 2016-04-06 |
| Confocal GI Scope Intended to provide optical visualization of an therapeutic access to the Gastrointestinal Tract. This anatomy includes, but is not restricted to, the organs, tissues and subsystems: Esophagus, Stomach and Duodenum, and Large Bowel to the Cecum. The instrument is introduced via the mouth or rectum as decided by the anatomy being accessed when indications consistent with the need for procedure are observed in adult and pediatric patient populations. | Class II | 2016-04-06 |
Showing 5 of 26 recalls.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| American Society for Gastrointestinal Endoscopy | Co sponsors trial with | 1 |
| Virginia Commonwealth University | Co sponsors trial with | 1 |
| Mayo Clinic | Co sponsors trial with | 1 |
| PENTAX of America, Inc. | Co sponsors trial with | 1 |
| Geisinger Clinic | Co sponsors trial with | 1 |
Latest dated events (45)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-08-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-11-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-09-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 45 events.
Biomarker capability evidence (25)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APC | Trial collaborator | Named in trial inclusion criteria |
| FAP | Trial collaborator | Named in trial inclusion criteria |
| HGD | Trial sponsor | Named in trial inclusion criteria |
| HGD | Trial collaborator | Named in trial inclusion criteria |
| HGD | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 25 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.